in the future
RESEARCH AND DEVELOPMENT
Developing novel treatments for CNS conditions
Throughout our history, Supernus Pharmaceuticals, Inc. has built a robust research and development program. We apply proprietary technologies to develop novel treatments that are designed to improve the lives of patients with CNS conditions.
This dedication to research has resulted in a successful track record of developing and launching novel products.
From efficiency to efficacy
We are able to reduce the risks, costs, and time typically associated with pharmaceutical product development by focusing on drug compounds with established mechanisms of action. In addition, our technologies are designed to meet specific clinical efficacy needs with an improved safety and tolerability profile.
Products utilizing our technologies
These technologies have been utilized to create ten marketed products, including Trokendi XR® and Oxtellar XR® (Supernus), Adderall XR®, Intuniv®, and Mydayis® (developed for Shire, now Takeda), and Orenitram® (developed for United Therapeutics Corporation).
Laying the foundation for new
therapies and innovations
Supernus Pharmaceuticals, Inc. is focused on developing products to meet the medical needs in the areas of neurology and psychiatry. To learn more about our current clinical trials for our product candidates, please visit www.ClinicalTrials.gov.
Innovative product candidates
Supernus is committed to the development of innovative product candidates in neurology and psychiatry. Below are our product candidates and their status in our pipeline.
Hypomobility in Parkinsons's disease
For the treatment of hypomobility in Parkinson’s disease
For the treatment of treatment-resistant depression
For the treatment of severe epilepsy